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Abstract: Multiple studies have reported that surface enhanced laser desorption/ionization time of ﬂ  ight mass spectroscopy 
(SELDI-TOF-MS) is useful in the early detection of disease based on the analysis of bodily ﬂ  uids. Use of any multiplex 
mass spectroscopy based approach as in the analysis of bodily ﬂ  uids to detect disease must be analyzed with great care 
due to the susceptibility of multiplex and mass spectroscopy methods to biases introduced via experimental design, patient 
samples, and/or methodology. Speciﬁ  c biases include those related to experimental design, patients, samples, protein 
chips, chip reader and spectral analysis. Contributions to biases based on patients include demographics (e.g., age, race, 
ethnicity, sex), homeostasis (e.g., fasting, medications, stress, time of sampling), and site of analysis (hospital, clinic, 
other). Biases in samples include conditions of sampling (type of sample container, time of processing, time to storage), 
conditions of storage, (time and temperature of storage), and prior sample manipulation (freeze thaw cycles). Also, there 
are many potential biases in methodology which can be avoided by careful experimental design including ensuring that 
cases and controls are analyzed randomly. All the above forms of biases affect any system based on analyzing multiple 
analytes and especially all mass spectroscopy based methods, not just SELDI-TOF-MS. Also, all current mass spectroscopy 
systems have relatively low sensitivity compared with immunoassays (e.g., ELISA). There are several problems which 
may be unique to the SELDI-TOF-MS system marketed by Ciphergen
®. Of these, the most important is a relatively low 
resolution (±0.2%) of the bundled mass spectrometer which may cause problems with analysis of data. Foremost, this 
low resolution results in difﬁ  culties in determining what constitutes a “peak” if a peak matching approach is used in 
analysis. Also, once peaks are selected, the peaks may represent multiple proteins. In addition, because peaks may vary 
slightly in location due to instrumental drift, long term identiﬁ  cation of the same peaks may prove to be a challenge. 
Finally, the Ciphergen
® system has some “noise” of the baseline which results from the accumulation of charge in the 
detector system. Thus, we must be very aware of the factors that may affect the use of proteomics in the early detection 
of disease, in determining aggressive subsets of cancers, in risk assessment and in monitoring the effectiveness of novel 
therapies.
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Introduction
Surface enhanced laser desorption/ionization time of ﬂ  ight mass spectroscopy (SELDI-TOF-MS) is 
a relatively new high throughput proteomic technique that has been reported to be useful in the early 
detection of disease. Speciﬁ  cally, SELDI-TOF-MS has been used to analyze samples of body ﬂ  uids 
to aid in the early detection of multiple neoplastic processes. Serum has been the major bodily ﬂ  uid 
utilized in most studies reported to date (Table 1).
Before any attempt is made at analysis of data of any form, the statistician / bioinformaticist should 
be thoroughly familiar with the source and accuracy of the data. The obvious trite statement applies: 
junk to the statistician equals junk from the statistician; thus, care should be taken to understand the 
quality of the data prior to analysis. The purpose of this manuscript is to alert those analyzing SELDI-
TOF-MS, other mass spectroscopy techniques, and other proteomic data of the potential sources of 
incorrect, inaccurate and/or biased data. The sources of problematic data can be subdivided into the 
following: experimental design, patient, sample, protein chip, chip reader, measures of the spectrum 
including peak identiﬁ  cation, peak comparisons, and algorithms of spectral analysis.
Experimental Design
The importance of careful experimental design involves each of the potential sources of biases listed 
above. For example, great care must be taken in identifying the patients to be studied and especially in 87
Grizzle, Semmes, Bigbee et al
Cancer Informatics 2005:1 1-1
carefully choosing control patients. For example, 
how does one ensure that controls do not have the 
subclinical form of the disease being studied? As 
part of the experimental design, the type of sample 
to be analyzed needs to be considered; for example, 
would serum, plasma, urine, saliva, cytological 
specimens, or combinations of these be the best 
samples to study.
Also, samples from cases and controls must be 
collected, processed and stored consistently. The 
use of SELDI-TOF-MS in early detection usually 
requires processing of samples using robotics, 
performing the assays in triplicate, and consistency 
in processing (e.g., dilution) of the sample before 
adding the triplicate of the sample to the chip. The 
type of chip(s) should be selected before the 
experiment (Table 2) and enough chips from one lot 
should be assembled to complete the experiment 
if practicable within the shelf lives of chips.
Samples should be applied to the chip in a manner 
selected to prevent bias and errors introduced from 
the methodology. Thus, because random and con-
sistent errors may arise due to spot, chip, and day 
of assay, error canbe minimized by ensuring that 
Table 1: Summary of some of the SELDI/MALDI-TOF-MS Cancer Case/Control Serum Proteomic Proﬁ  ling Studies
Organ 
Site
ProteinChip 
Type
Number of Patients 
in Learning / Training 
Set
Results of Training Set Number of 
Patients in Test 
Set
Results of Test Set Number 
of Peaks
Reference
Controls Cancer Sensitivity Speciﬁ  city Controls Cancer Sensitivity Speciﬁ  city
Bladder WCX2 weak 
cation 
exchange
104 87 87 84 18 21 78 67 7 1
Breast IMAC3 nickel 
activated
66 42 N/A N/A 66 103 85
2 91
2 32
Breast IMAC3-Cu 
SAX-2
89
3 
30
6
45 
30
6
N/A 
82 (84)
4 
90
N/A 
85 (90)
4 
97
89
3
30
6
45
30
6
N/A 
80 (78)
5 
90
7
N/A 
79 (83)
5 
93
7
4
3
4
3
Head 
and Neck
IMAC3 copper 
activated
75 75 91 88 27 24 83 100 3 4
Head 
and Neck
MALDI 95 66 N/A N/A 48 33 73
8 90
8 45 5
Kidney WCX2 
weak cation 
exchange
21 15 N/A N/A 21 15 87
9 85
9 56
Liver IMAC3-Cu 
WCX2 
20 38 N/A N/A 20 38 90
10 92
10 6 4 7
Lung WCX2 weak 
cation 
exchange
51 30 N/A N/A 31 15 93 97 3 8
Ovary C16 hydropho-
bic interaction
50 50 100(?) 100(?) 66 50 100 95 8 9
Ovary SAX2 strong 
anion 
exchange
73 67 96 83 22 22 95 91 14 10
Pancreas IMAC3-Cu 
WCX
120 60 N/A N/A 120 60 78
2 97
2 91 1
Prostate IMAC3 copper 
activated
159 167 98 94 30 30 83 97 9 12
Prostate C16 hydropho-
bic interaction
25 31 NR
11 NR
11 228 38 95 78 7 13
Prostate IMAC3-Cu 
WCX2
30 44 N/A 
89
1
N/A 
87
1
26 62 66 
63
85
1
38 
77 
85
1
5 
6 
3
1
14
Legend
1Combined performance of peaks from both IMAC-Cu and WCX2 ProteinChip® arrays
2Bootstrap cross-validation using all patients and controls
347 healthy controls, 42 patients with benign breast disease
4Versus healthy controls and benign disease, respectively
5Cross-validation versus healthy controls and benign disease, respectively
6Randomly selected 30 cases and controls
7Cross-validation using combined performance of peaks from both IMAC-Cu and SAX ProteinChip
® arrays
8Cross-validation using two-thirds of cases and controls as the training set, one third as the test set
9Results of ﬁ  ve independent simulation studies
10Cross-validation using combined performance of peaks from both IMAC-Cu and WCX2 ProteinChip
® arrays
1
1Training set results not reported88 Cancer Informatics 2005:1 1-1
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each of the triplicates is placed on a different spot 
(e.g., not more than one of a triplicate on spot A), 
each on a different chip (i.e., no more than one of 
the triplicates on the same chip) and each of the 
triplicates should be analyzed on a different day. 
Given these restrictions, cases and controls should 
then be applied randomly and blindly to the chip 
based upon statistical considerations. Thus, each 
of the triplicates is analyzed within one of three 
groups. Each of these groups should be analyzed 
on separate days. Spots and chips are randomly 
assigned except that spots and chips must be dif-
ferent on each of the triplicates of one specimen 
(see Table 3).
Similarly, a consistent aliquot of a standard 
control sample should be used (at least one per 
chip) and the standard control sample also should 
be loaded on chips without bias as to the spot on 
the chip to which it is loaded. The chip should be 
prepared using a robotic system within one day 
of analysis. The energy absorbing molecule 
(EAM) should be chosen with care to match the 
molecular weight range of interest. If a whole 
spectrum is of interest 1000 Daltons to 200,000 
Daltons, then multiple runs of a sample will be 
necessary, each run over a speciﬁ  c molecular 
weight range with a separate set of triplicates and 
different adjustments including to laser and 
detector. For each range of interest (e.g., 1 kD to 
15 kD) an EAM should be selected and the 
machine should be calibrated for this spectral 
area. EAMs vary in efﬁ  ciency based upon the 
molecular weight range being analyzed. Thus, an 
area such as from 50 kD to 100 kD will require a 
different EAM and a speciﬁ  c set of molecular 
weight standards (e.g., 5 to 7 puriﬁ  ed proteins) 
which bridge these molecular weights. The points 
at which the laser samples the spots, should be 
selected so as to not exhaust the sample-EAM 
matrix (Figure 1). If a directed (e.g., peak identi-
ﬁ  cation) approach to analysis is to be used, a 
careful, consistent method of peak identiﬁ  cation 
should be utilized and the alignment of peaks 
should be consistent. The instrument should be 
calibrated periodically and the consistency of the 
instrumental output should be veriﬁ  ed using the 
standard samples as part of the quality control 
program. Finally, there must be a consistent 
approach to the analysis of data.
Patient and Controls
The general approach of proteomics is to compare 
one condition with another; thus, in studies 
involving the early detection of a disease, patients 
with the disease (cases) are compared with 
Table 2: Types of chip
Old Designation Current Chip Biochemical Action of Surface Chemistry
IMAC3 IMAC30 (with hydrophobic 
barrier)
Bivalent metals can be attached to the chip. Proteins that bind to these divalent metals (eg, 
Cu
+2) are bound by the chip.
WCX2 Same (CM10 mimics WCX2 
but does not replace)
This is a weak cation exchange chip. It contains negatively charged (anionic) carboxylate groups 
that will bind proteins with positively charged areas containing high numbers of lysine, arginine, 
and/or histidine amino acids.
H4 Same (C16 contains 16 CH3) The chip contains multiple chains, each composed of 16 methylene groups. This very hydrophobic 
microenvironment binds molecules that are hydrophobic.
SAX2 Q10 (with hydrophobic barrier) Strong anion exchanger which is composed of quartenary ammonium groups that are charged 
positively. This chip will bind proteins/peptides with regions rich in acidic groups,
NP1 and NP2 NP20 General protein binding surface which binds via serine, threonine or lysine
PS1 and PS2 PS10 / PS20 Binds via attachment of capture molecules such as antibodies, binding proteins, etc.
SENDID Incorporates EAM into chip.
Table 3: Potential Organization of Triplicates of Samples on Chips (Spots and 
Chips Randomly Chosen in Each Group)
Group 1 Group 2 Group 3
Sample 1A, Spot C, 
Chip 7
Sample 1B, Spot A, 
Chip 5
Sample 1C, Spot F, 
Chip 2
Sample 2A, Spot D, 
Chip 5
Sample 2B, Spot C, 
Chip 3
Sample 2C, Spot A, 
Chip 4
Sample 3A, Spot A, 
Chip 4
Sample 3B, Spot F, 
Chip 1
Sample 3C, Spot G, 
Chip 7
...
...
...
Sample NA, Spot D, 
ChipM
Sample NB, Spot G, 
Chip M-5
Sample NC, Spot B, 
ChipM+189
Grizzle, Semmes, Bigbee et al
Cancer Informatics 2005:1 1-1
patients without the disease (controls). The ﬁ  rst 
very important issue is to identify what are the 
clinical (research) and other parameters that 
deﬁ  ne a good control. For example, controls for 
prostate cancer (PCa) should not have prostate 
cancer but should be males who have conditions 
such as benign prostatic hyperplasia (BPH) which 
may mimic PCa as well as be within the age range 
that PCa usually occurs  50 years of age. 
Familial cases may need separate controls. The 
usual normal range for PSA is  4 ng/ml; 
however, based upon the Prostate Cancer 
Prevention Trial (PCPT) about 20% of patients 
with PSA values  4 ng/ml, have PCa (Thompson 
et al, 2004). Similarly, about 60% of patients with 
PSA values from 4 to10 ng/ml have no PCa but 
rather BPH. Men with PSA values much greater 
than 100 ng/ml are more likely to have PCa 
(Urban et al, 1999). Although no control group 
is perfect, one might select controls for a serum 
based study of PCa as being males with PSA  
10 ng/ml, a normal digital rectal examination, 
normal prostatic ultrasonography, and a recent 
negative biopsy (at least sextant) of the prostate 
taken after the sample of serum was obtained 
because biopsy of the prostate may “activate” the 
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Figure 1: Figure 1 demonstrates the spectral decreases upon multiple laser shots in same area. The same sample was applied to spots A, 
B, and C and these spots were analyzed initially with 5 laser shots per spot to demonstrate consistency of spectral pattern. Following 3 
additional samplings of spot B, at 5 laser shots each at the same site, the decrease in the spectrum is clear (4
th 5 shot read of spot B). After 
a total of 10 and 14 5 shot samplings at the same site on spot B, a marked decline in sample intensity was noted (10
th read of spot B and 
14th read of spot B respectively).90 Cancer Informatics 2005:1 1-1
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prostate for several weeks subsequently (Urban 
et al, 1999). Controls above 4 ng/ml but less than 
10 ng/ml are chosen because most samples in this 
range do not have PCa and controls should not 
exclude proteomic changes secondary to benign 
prostatic hyperplasia (BPH) (Grizzle et al, 2003, 
2005). Such controls might be collected prospec-
tively or their samples might exist in a tissue 
bank; however, it is critical that all conditions of 
cases (site, collection, storage, etc.) match 
controls. Because various metabolic states may 
affect proteomic assays (e.g., diurnal rhythm, 
chronic diseases, stress), the metabolic and other 
conditions under which the control samples were 
collected should mirror the conditions under 
which the samples from patients with PCa were 
collected. For example, either a group of males 
all of whom had rheumatoid arthritis or a group 
of males all of whom had undergone a glucose 
challenge 2 hours prior to obtaining samples 
would be a bad control group for a group of males 
with PCa and the normal incidence of rheumatoid 
arthritis and a fasting state prior to sampling. It 
is necessarythat such conditions average out and 
thus their contributions to the analysis of spectral 
patterns would be noise. The patterns of eating 
of disease groups can result in an important bias 
because some medical facilities may require 
patients to be fasting when visiting a clinic/
hospital while other locations may not. Identifying 
members of the control groups for other cancers 
is just as demanding. Note that the age, sex and 
health of the control group should match the case 
group. One way to approach this is to require the 
same number of controls as cases be collected 
from each site (i.e., if 30 cases of PCa are 
collected from site A, then site A would also 
supply 30 controls).
Because some of the spectral peaks in SELDI-
TOF-MS analysis have been attributed to nonspe-
cific inflammatory peaks, in some studies of 
neoplasia it would be useful to have additional 
separate groups of patients without the cancer 
being studied to identify non-speciﬁ  c proteins 
which may be associated with conditions such as 
rheumatoid arthritis, systemic lupus erythematosis, 
sepsis, and other tumors. Such groups should not 
be used in training the algorithm but rather to test 
the algorithm as to the speciﬁ  city of the informative 
peaks selected by the algorithm.
Speciﬁ  c issues to consider in the selection of 
members of the case group would be the type(s) 
of cancers studied. If the focus were to be on early 
detection of PCa, one would not want to evaluate 
samples from males who had metastatic PCa at the 
time of sampling. Similarly, Gleason scores might 
be chosen to separate more indolent PCa (Gleason 
 6) from more aggressive (Gleason  7) PCa. 
Ultimately in early detection, analysis of samples 
of serum obtained one to several years prior to the 
diagnosis of a specific cancer is necessary 
(Pepe et al., 2001).
When the cancers of an organ such as lung 
are of various types, e.g., squamous cell carci-
noma, adeno-carcinoma, bronchoalveolar, small 
cell (oat cell) un-differentiated and “other”, then 
tumor
tissue 
reaction
Venous and 
lymphatic fluids 
containing tumor, 
im m u no lo gical and  
tissue-reaction 
products and their 
metabolites
liver
Urine with tumor and tissue-
reaction products and metabolites
kidney
Lymph 
node
Figure 2: Figure 2 demonstrates that molecular markers in bodily 
ﬂ  uids that may be used in the diagnosis of cancers may come from 
multiple sources. The tumor itself may produce markers such as CEA 
(colorectal cancer) that are produced by the tumor. Other tumor 
products may circulate and induce changes in distant tissues (e.g. 
liver and kidney) affecting the synthesis or metabolism of speciﬁ  c 
molecules. The stromal and inﬂ  ammatory response to the tumor may 
also modulate proteins (e.g, cytokines) in serum.
TUMOR 
MOLECULAR 
FEATURES
MOLECULAR 
FEATURES 
OF NORMAL 
TISSUE
CEA 
TAG-72
CA125
MUC-2
LEWIS Y
Normal and Tumor Markers-PSA,     
Alpha1 -ANTITRYPSIN
MOLECULES AND 
METABOLITES OF NORMAL 
TISSUES -ACTIN              
Immunological, 
tumor surround, 
distant reaction
Figure 3: Figure 3 emphasizes that some markers such as oncofetal 
tumor molecules are produced directly by the tumor while other tissue 
speciﬁ  c molecules such as PSA may be produced by the uninvolved 
tissues in addition to the tumor. Patterns of all proteins in bodily ﬂ  uids 
depend upon multiple factors including where the contents of dying 
cells are dumped as well as the rate of cellular death.Grizzle, Semmes, Bigbee et al
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each type of cancer should be evaluated 
separately. Although it is possible that all types 
of carcinomas of the lung could be separated 
from controls by SELDI-TOF-MS analysis, 
more specific peaks will probably be identified 
if each type of tumor were analyzed as a separate 
group. For such cases, each type of tumor should 
utilize a different case group although the 
control group could remain the same, except for 
bronchoalveolar carcinoma which usually is not 
associated with smoking as a risk factor. Also, 
a separate algorithm should be developed and 
optimized for each type of tumor.
When an individual has cancer, multiple 
changes may occur in the spectral patterns of 
proteins in blood. As suggested in Figures 2 and 3, 
these changes include spectral peaks that correlate 
with molecules that are released from the tumor 
and molecules that are produced by local and 
distant responses to the tumor. Similarly, regula-
tory molecules may be released from the tumor 
and/or the epi-reaction and may modulate the 
production of proteins by distant tissues (e.g., 
acute phase reactants produced by the liver). The 
immune system also will produce reactions to the 
products of the tumor including cellular contents 
released into the circulation Other molecular 
changes may be modulated by tumors including 
the rate at which speciﬁ  c molecules are excreted 
or metabolized by the kidney or biliary-colorectal 
system. Also, speciﬁ  c proteolytic enzymes may 
be produced by a tumor or surrounding cells and 
these enzymes may affect patterns of proteins in 
serum and other bodily ﬂ  uids. Ultimately, carrier 
proteins may bind smaller molecules; this may 
affect their analysis, for example, by concentrating 
them (Grizzle et al, 2005). All these potential 
sources of molecular changes in the spectral 
proteins in serum may combine to form spectral 
patterns which may be characteristic of the 
presence of a speciﬁ  c disease, e.g., a speciﬁ  c type 
of tumor.
Molecular
Features of
Normal Condition
Second Patient
Distinct
Disease
Molecular
Features
Distinct
Disease
Response
Primary
Peak
Secondary
Peak Patient One
Figure 4: Figure 4 demonstrates two types of peaks observed in 
spectra when comparing cases with controls. The molecular features 
of the control lower spectrum demonstrates three peaks. These would 
usually be seen in any patient without disease. In the spectrum of 
the diseased patient, a new peak (primary peak) is present in the 
spectrum. This would probably result from a product produced 
because of the disease. Of interest, a peak (secondary peak) present 
in the spectra of most patients without disease is now absent from 
the spectrum of the diseased patient. Such peaks are not understood 
but may represent tumor-normal organ cross talk to reduce produc-
tion of a protein or the production of an enzyme by the diseased state 
which metabolizes the protein of the secondary peak.
NODULE
OF  BPH 
Products from
Dying Cells and
Duct Contents
e.g., PSA
Products of Dying
Cancer Cells Collect in
interstitial Space and are
Absorbed in to Vascular
and Lymphade Vessels
 
Contents of Duct
Including
Products of
Dying Cells and
Living Cells e.g.,
PSA
B
A
Figure 5: Figure 5A is a cartoon which suggests how the secretions 
of living cells and the contents of dying cells of normal prostatic glands 
may exit the body without being absorbed into the vascular system. 
In contrast, dying cells of prostate cancer dump their contents into 
the interstitutium and these products are likely to be absorbed into 
the vascular system. Figure 5B demonstrates that as benign prostatic 
hyper-plasia develops that glandular contents may be blocked from 
the usual pathway. Subsequently the glands may become dilated 
and/or inﬂ  amed and contents including PSA may leak from the lumen 
of the gland into the interstitial space.
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In spectra from cases and controls, two different 
types of informative peaks may be identiﬁ  ed. One 
type of informative peak is highest in the cases of 
cancer (Figure 4). We designate such peaks as 
“primary” because they are suggestive of a primary 
product arising because a tumor is present in a 
patient. The second type of informative peak is 
lower in the cases with cancer than in control serum 
(Figure 4). We designate such peaks as “secondary” 
because their presence suggests that the presence 
of the cancer in a patient causes a decrease in a 
peak that usually is present in serum of normal 
individuals. This suggests the presence of the 
tumor increases the degredation of the secondary 
peak either due to increased proteolytic activity or, 
the production of a strong binding protein. Also, 
such changes in peaks may occur via the modula-
tion of production of a molecular species and/or 
of excretion of molecules via kidney or biliary-
colorectal system, by binding and removal via the 
immune system, or via a combination of these 
processes.
Sometimes it is not the concentration of a 
molecular species that is produced by a tumor or 
that is present in the cells of tumors, but rather 
where the contents of tumor cells are released and 
the rate at which tumor cells die that control the 
levels of a protein in ﬂ  uids. For example, the cells 
of adenocarci-noma of the prostate (PCa), in 
general, have a lower concentration of prostatic 
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Figure 6: The bar graph of ﬁ  gure 6 demonstrates the decline in the 
peaks of three unidentiﬁ  ed proteins in serum that follow multiple 
freeze thaw cycles of samples of serum. The pattern of decline var-
ies with speciﬁ  c peaks; however, most peaks do not decline greatly 
until after at least three freeze thaw cycles.
5000 7000 10000
Aliquot of Sample 
(#20) Stored at
- 80°C        
Second aliquot of 
Sample (#20) 
Stored ONLY at       
- 80°C for Ten 
Additional Months
Aliquot of Sample 
(#20) Transferred 
from- 80°C and 
Stored for 3 Months 
at -20°C
Aliquot of Sample 
(#20) Stored at       
-2 0 ° C  f o r  5  M o n t h s
Aliquot of Sample 
(#20) Stored at         
-2 0 ° C  f o r  7  M o n t h s
Aliquot of Sample 
(#20) Stored at       
- 20°C for 8 Months
Second aliquot of 
Sample (#20) 
Stored at -20°C for 8
Months
B
C A
Figure 7: Figure 7 demonstrates that 
storage of aliquots of a sample at -20°C 
(non-self defrost) for more than 6 months 
results in changes in peak amplitudes 
(A) and peak amplitude ratios (B vs C). 
Such changes were not noted on stor-
age of an aliquot from the same original 
specimen for 10 months at -80°C.
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speciﬁ  c antigen (PSA) than the cells of normal 
prostatic tissues. How then can PSA be a sensitive 
marker of the early detection of PCa? First, when 
the cells of normal prostatic tissues die, they dump 
their contents into the lumina of the normal prostate 
glands and the contents of the glands are ultimately 
cleared in the ejaculate (Figure 5 A). In contrast, 
when the cells of PCa die, they are not located in 
an intact ductal system and thus these cells dump 
their contents into the interstitial space so that their 
contents are absorbed by the vascular-lymphatic 
system (Figure 5A). Similarly, if benign ducts 
become blocked by changes of BPH or by the 
accumulation of concretions, their wall may leak 
products such as PSA into the interstitial space 
(Figure 5B).
Samples
The choice of the best type of sample is controversial. 
Some investigators use plasma to avoid the 
activation of the coagulation system and consequent 
release of factors from platelets and proteins 
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8000 – 100,000 Da
B
Figure 8: The spectra in Figure 8A (titled 
“Cancer markers from Serum on IMAC 
Protein Chips 2000 - 8000 Da”) and 8B 
(titled “Cancer markers from Serum on 
IMAC Protein Chips 8000 - 100,000 Da”) 
demonstrate some of the informative 
spectral peaks (e.g. peak locations) 
reported in the literature for the early 
detection of prostate, breast and head 
and neck tumors as detected using 
serum samples on IMAC copper acti-
vated protein chips.
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associated with coagulation. Others prefer serum 
in which coagulation has removed some high 
concentration proteins.
Once the type of sample is chosen, the sampling 
conditions need to be standardized. The choice of 
sample collection and storage containers may 
inﬂ  uence spectral results. While glass sample 
collection tubes may activate speciﬁ  c proteins, 
plastic collection and storage containers may 
contaminate specimens with plastic components. 
Because plastics usually are poly-molecular forms 
(e.g., polyvinyl chloride), plastic contaminants 
may present as repeating spectral peaks, each 
separated by a standard molecular weight, usually 
about 100 to 200 Daltons. Similarly, additives to 
tubes (e.g., anticoagulants such as heparin) may 
inﬂ  uence spectral patterns. A minimum sample 
size should be selected and samples should be 
aliquoted to minimum sizes shortly after collection 
to avoid repeated freeze-thaw cycles. As demon-
strated in Figure 6, peak amplitudes may decline 
upon several freeze-thaw cycles. The conditions 
between the collection of samples and storage of 
specimens should be standardized. It also is 
important to have conditions of storage consistent; 
for example, if cases are to be collected in the next 
two years, one does not want to use controls from 
an archival serum collection stored for 10 years 
or more at -70°C. It is critical that samples be 
stored at best at -70°C or colder. Storing samples 
at -20°C or warmer, even in a non-self defrost 
freezer, may result in degredation of proteins as 
measured by spectral changes (Figure 7). We are 
aware of MALDI-TOF-MS data that indicate 
spectral peaks do not change upon storage at -70°C 
or colder over a 4 year period.
The proteomic systems may be very sensitive 
to small errors in pipetting and thus robotic pro-
cessing of samples including the addition of EAM 
to sampling spots is recommended. In some cases 
the protocol may call for removal of proteins 
normally present at high concentrations (e.g. 
albumin, immunoglobulins). The binding of 
proteins/peptides to carrier proteins (e.g., albumin) 
may act to concentrate low molecular weight 
proteins normally expected to be present in low 
concentrations or to be of small size which can be 
cleared rapidly by renal excretion (Grizzle et al, 
2005). One must be aware that the method of 
removal of carrier proteins also may remove small 
molecules at low concentrations that are carried 
by, for example, albumin. Also, whether or not 
samples are to be diluted must be considered. It 
should be noted that the results may be sensitive 
to the extent of dilution so various dilutions should 
be tested on aliquots of the same sample. Fore-
most, it is critical that cases and controls be col-
lected, processed and stored under the same 
general conditions.
Protein Chip
The SELDI system is designed for relatively high 
throughput analysis by chromatographic separation 
of speciﬁ  c categories of molecules from complex 
molecular mixtures such as serum and for efﬁ  -
ciently analyzing these molecules via time of ﬂ  ight 
mass spectroscopy. This task is performed using 
“protein chips” which are metal chips with usually 
8 sample spots. Each spot is an area of the metal 
chip to which speciﬁ  c chromatographic material 
is strongly attached. When complex samples are 
applied to a spot, molecules with speciﬁ  c bio-
chemical properties are chromatographically 
bound by the spot and are retained on the spot even 
after the spot is washed extensively to remove 
unbound material. The chips currently available 
from Ciphergen are listed in Table 2. For a more 
detailed explanation of how SELDI-TOF-MS oper-
ates see references 2, 12 and 19.
It is important to understand that each type of 
chip (e.g. IMAC3 - copper activated) will produce 
a different protein spectra from the same sample 
than that produced by other types of chips. There-
fore, using the same sample of serum, data from 
an IMAC3 Cu chip will be different from data 
obtained using an H50 chip. However, when 
similar chips are used, IMAC3 copper activated 
and IMAC30 copper activated, the spectra are 
more likely to be similar but not necessarily iden-
tical. Although users should be aware that when 
Ciphergen adds the hydrophobic boundary other 
parameters of the binding may change such that 
binding to the WCX2 chip differs from binding to 
the CM10 chip. In analysis, data on the same peaks 
from different types of chips should not be com-
bined in training sets or testing sets because one 
cannot be certain that identical peaks are being 
evaluated.
Several issues related to chip characteristics 
may affect the results of SELDI-TOF-MS 
analysis. First, proteins present in large concen-
trations (10,000 “X” of 10 kD protein) which 
have the same binding characteristics of proteins 
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present at lower concentrations, 100 “X” of 15 
kD protein may saturate binding characteristics 
of sample spot and prevent the retention of the 
protein present at a lower concentration.
Once proteins are bound to the chip and the 
EAM is applied, the laser may not free/ionize 
equivalently all the proteins that were bound 
originally. As previously demonstrated in Figure 1, 
after 20 to 30 laser shots to the same site, there is 
a marked deterioration in the spectral characteristics 
from that site.
Spectra
Careful calibration of the instrument with proteins 
of known molecular weight and binding charac-
teristics is extremely important because the raw 
data are measured as times of ﬂ  ight of the ions and 
the software must convert these “times” to 
molecular weights via the calibration step. Before 
samples are run, the molecular weights of interest 
should be determined and the instrument should 
be calibrated using molecular weight standards 
which are appropriate for the molecular weight 
range of interest. As discussed, if various areas of 
the spectrum are of interest, multiple triplicates of 
the same sample should be run for each molecular 
weight range of interest. Thus a set of peaks in the 
range of 2,000 to 15,000 Daltons should be mea-
sured and analyzed separately from a set of peaks 
from 30,000 to 60,000 Daltons. This includes using 
a different EAM as well as a different set of cali-
bration standards covering the range of 30 kD to 
60 kD. At each range different laser and detector 
settings also may be required.
Analysis of Spectra
Once the spectral data are obtained either a 
“directed” or “non-directed” approach is taken in 
analysis. In the “non-directed” approach, an 
amplitude for each mass to charge (M/Z) position 
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Figure 9: Figure 9A is depicts cancer markers from various chip types, 0 to 4000 Da. Figure 9B depicts cancer markers from various chip 
types 4000 to 8000 Da. Figure 9C depicts cancer markers from various chip types 8000 to 20,000 Da. Figure 9D depicts cancer markers 
from various chip types 20,000 to 100,000 Da. The spectra in Figure 9 A-D demonstrate the informative spectral peaks (e.g., peak locations) 
reported in the literature (except those of Figure 8) for the detection of neoplasias in multiple organ systems using multiple samples and 
various types of protein chips.
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in the spectra is determined and analysis begins 
after this determination. This approach may be 
more sensitive to changes in peak location than 
the “directed” approach in which peaks are iden-
tiﬁ  ed and peaks are matched based upon the reso-
lution (± 0.2% mass) of the Ciphergen instrument. 
Alternatively a method of analysis based on deter-
mining the area under the curve (AUC) of spectral 
peaks can be used (Meleth et al, 2005). Subse-
quently the amplitude or the area under the curve 
of a spectra peak is determined. For each such 
measurement, informative peaks and AUCs are 
identiﬁ  ed that separate disease from non-disease. 
Before choosing the ﬁ  rst peak for an analytical 
algorithm, one could make a controversial distinc-
tion among peaks classifying them either as pri-
mary or secondary and evaluating their typical 
amplitudes or AUC, peaks with smaller ampli-
tudes or AUCs may be less reproducible and hence 
less reliable in algorithms. Also, even though it 
has been proposed that changes that are greater in 
magnitude cause secondary peaks to decrease in 
disease patients in comparison to increases in 
primary peaks, the choice for the ﬁ  rst peak in a 
decision algorithm might be a primary peak with 
a high amplitude due to the potentially more 
straight forward relationship with the disease 
process and a greater reliability in comparisons 
of disease with non-disease.
How variable is the peak location (resolution) 
and peak amplitude when samples are run on the 
same day on the same machine? On different days 
on the same machine? On different machines? 
Our validation study of prostate cancer (Semmes 
et al, 2005) has demonstrated that SELDI-
TOF-MS machines at widely separated sites can 
be calibrated and standardized and that separate 
sites can identify blindly the same diagnostic 
peaks that previously have been shown to be 
important in the diagnosis of prostate cancer 
(Semmes et al, 2005).
All areas of the SELDI-TOF-MS spectrum are 
not the same from the standpoint of the early 
detection of disease. Areas of molecular weight of 
less than 1000 are in an area that is not standardized 
so that molecular sizes in this region cannot be 
determined accurately. Also, in the spectral area of 
less than 2000, peaks may be secondary to com-
ponents of the energy absorbing molecule and/or 
other contaminants from, for example, plastics and 
the anti-coaogulants in collection tubes. Instrumen-
tal noise may in addition be present in spectral 
areas less than 1000 M/Z. In the spectral area above 
50,000 D, many molecular species such as albumin 
are present in very high concentrations. Also, in 
our experience, the system is not very useful in 
detecting proteins of 50 kD or greater without 
adjustments (Malyarenko et al, 2005).
Because the Ciphergen system is a low 
resolution mass spectrometer, a protein of 
molecular weight 10,000 D with a concentration 
of 1000 “X” will prevent a protein of 10,020 D 
with a concentration of 100 “X” and similar 
binding and release characteristics for the chip 
utilized from being detected.
Diamandis has published several criticisms of 
the general SELDI approach (Diamandis 2003, 
2004). In each of these criticisms Diamandis has 
argued that for the same type of cancer, different 
laboratories should be identifying the same 
peaks. This actually should not be the case and 
even for prostate cancer the identiﬁ  cation of 
different peaks should be the rule rather than 
unusual result (Grizzle and Meleth, 2004) 
because different studies have used different 
chips which bind different proteins and because 
100s of peaks may separate cancer from non-
cancer and this plus the algorithms chosen may 
result in different peaks being selected. Similarly, 
Diamandis (23,24) and others have argued that 
SELDI may be identifying peaks that are 
characteristic of inflammatory aspects of 
neoplasia or epiphe-nomena of cancers in general 
(Malik et al, 2005). This clearly is an important 
issue not only with SELDI-TOF-MS but also with 
any current forms of mass spectroscopy which 
have sensitivities of orders of magnitude less than 
the sensitivities which are necessary to detect 
tumor products such as PSA and CA125. Some 
of the peaks identiﬁ  ed to date and their association 
with a speciﬁ  c cancer are demonstrated in Figures 
8 and 9. Of interest is that peaks for various 
cancers have varied to date; however, based on 
our argument this may be serendipitous rather 
than an indication that the peaks are speciﬁ  c for 
a speciﬁ  c cancer.
Types of measurements and a discussion of 
issues regarding what is to be measured in spectra 
and various analytical approaches are discussed 
extensively in the other manuscripts of the volume 
and are beyond the scope of this manuscript. How-
ever, it is critical that all studies published include 
a learning/training set of samples followed by 
analysis of a test set of independent samples.
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